ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Davisite
|
146 |
45K |
26 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
146
|
45K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Davisite
|
146 |
45K |
32 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
146
|
45K
|
32
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
Davisite
|
146 |
45K |
72 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
146
|
45K
|
72
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
38 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
168
|
48K
|
38
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
40 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
168
|
48K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
42 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
42
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
35 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
83K
|
35
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
11K |
4.0M |
66 |
09/07/24 |
09/07/24 |
General
|
11K
|
4.0M
|
66
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
11K |
4.0M |
28 |
09/07/24 |
09/07/24 |
General
|
11K
|
4.0M
|
28
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
40 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
24 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
24
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
58 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
58
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
29 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
29
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
44 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
44
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
21 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
Davisite
|
905 |
273K |
37 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
905
|
273K
|
37
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
38 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
38
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
Davisite
|
391 |
83K |
34 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
83K
|
34
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
19 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
168
|
48K
|
19
|
|
ASX - By Stock
|
FRE |
Re:
Ann: Change of Director's Interest Notice - Peter Molloy
|
|
Davisite
|
4 |
2.5K |
11 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
4
|
2.5K
|
11
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
11K |
4.0M |
30 |
05/07/24 |
05/07/24 |
General
|
11K
|
4.0M
|
30
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
42 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
42
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
11K |
4.0M |
25 |
05/07/24 |
05/07/24 |
General
|
11K
|
4.0M
|
25
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
11K |
4.0M |
84 |
05/07/24 |
05/07/24 |
General
|
11K
|
4.0M
|
84
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
19 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
19
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
51 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
51
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
84 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
168
|
48K
|
84
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
43 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
43
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
13 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
13
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
67 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
67
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
14 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
14
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
61 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
61
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
58 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
58
|
|
ASX - By Stock
|
IMU Biotech |
Re:
Azer Cell Toxicity from Ken
|
|
Davisite
|
86 |
32K |
15 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
86
|
32K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
42 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
38K
|
42
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
Davisite
|
168 |
48K |
61 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
168
|
48K
|
61
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Davisite
|
11K |
4.0M |
9 |
02/07/24 |
02/07/24 |
General
|
11K
|
4.0M
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
33 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
38K
|
33
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
35 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
38K
|
35
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
Davisite
|
130 |
38K |
68 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
38K
|
68
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
Davisite
|
2.3K |
790K |
45 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
2.3K
|
790K
|
45
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
Davisite
|
2.3K |
790K |
36 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
2.3K
|
790K
|
36
|
|
ASX - By Stock
|
ILA |
Re:
Ann: Trading Halt
|
|
Davisite
|
16 |
3.9K |
12 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
16
|
3.9K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
Davisite
|
2.3K |
790K |
87 |
30/06/24 |
30/06/24 |
ASX - By Stock
|
2.3K
|
790K
|
87
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
Davisite
|
2.3K |
790K |
15 |
30/06/24 |
30/06/24 |
ASX - By Stock
|
2.3K
|
790K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
Davisite
|
2.3K |
790K |
101 |
30/06/24 |
30/06/24 |
ASX - By Stock
|
2.3K
|
790K
|
101
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Webcast slides for new Efti clinical data in 1st line HNSCC
|
|
Davisite
|
100 |
57K |
31 |
27/06/24 |
27/06/24 |
ASX - By Stock
|
100
|
57K
|
31
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
Davisite
|
80 |
25K |
9 |
27/06/24 |
27/06/24 |
ASX - By Stock
|
80
|
25K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
Davisite
|
80 |
25K |
3 |
27/06/24 |
27/06/24 |
ASX - By Stock
|
80
|
25K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
Davisite
|
80 |
25K |
2 |
27/06/24 |
27/06/24 |
ASX - By Stock
|
80
|
25K
|
2
|
|